Preclinical WebsiteClinical Website
Last Updated Date: July 06, 2024

What is the cuprizone-induced demyelination model of multiple sclerosis?

Multiple sclerosis (MS) is a prevalent, chronic, autoimmune demyelinating disorder of the central nervous system (CNS), affecting over 2.8 million people globally (Walton, 2020). In MS research, various preclinical models are used to replicate different aspects of the disease, including demyelination models, such as lysolecithin (LPC) mouse & rat models and the cuprizone mouse model (Dedoni, 2023).

Illustration of demyelination in the corpus callosum of cuprizone-fed mice

Illustration of demyelination in the corpus callosum of cuprizone-fed mice. A normally myelinated corpus callosum is shown on the left and the partially demyelinated white matter tract is shown on the right.

The cuprizone model is a widely-used toxin-induced multiple sclerosis model (Kipp, 2024; Zhan, 2020). Cuprizone (C14H22N4O2), or oxalic acid bis [cyclohexylidene hydrazide], is a copper-chelating agent that, when administered orally, induces the death of mature oligodendrocytes and subsequent demyelination of specific white matter tracts in the rodent brain (Dedoni, 2023). This model involves the activation of innate immune cells within the brain, but T and B lymphocytes do not play a central role (Wolf, 2018), thereby distinguishing it from other MS models that involve the adaptive immune system, such as Experimental Autoimmune Encephalomyelitis (EAE), Theiler’s Murine Encephalopathy Virus (TMEV), and other viral models of MS (Dedoni, 2023). Cuprizone-induced demyelination is not lymphocyte-dependent and occurs even in lymphocyte-deficient recombination activating gene (Rag) knockout mice (Hiremath, 2008).

Molecular structure of cuprizone

Molecular structure of cuprizone; C14H22N4O2; molecular weight: 278.45 g/mol

The cuprizone model allow researchers to dissect and investigate specific mechanisms in the progression of MS. This rodent model can be divided into two phases: (1) initial demyelination in the corpus callosum and other brain regions, such as the superior cerebellar peduncles and cerebral cortex (Vega-Riquer, 2019), which is accompanied by activation of the innate immune system, and (2) significant remyelination of exposed axons once cuprizone treatment is terminated (Gharagozloo, 2022). 

In practice, mice are fed cuprizone for 5-6 weeks. This approach leads to selective oligodendrocyte stress and death, resulting in acute demyelination of distinct brain subregions, extensive microglial activation and astrocytic proliferation, a breakdown of the axonal transport mechanisms (Rühling, 2019), and, in more chronic models, overt axonal damage (Lindner, 2009). The exact mechanisms behind oligodendrocyte degeneration are not fully understood, but may include mitochondrial disruption due to a cuprizone-induced copper deficit, ferroptosis (Jhelum, 2020), and endoplasmic reticulum stress responses. 

The timeline of cuprizone's effects is well-documented. In the early phase, within the first week of treatment, oligodendrocyte death can be observed as early as two days after treatment begins. There is early activation of astrocytes (Kipp, 2023) and microglia (Gudi, 2014), followed by rapid loss of mature oligodendrocytes, with approximately 65% lost by the second day and 80% by the end of the first week (Kipp, 2023). In the intermediate phase, spanning 1 to 3 weeks, the loss of oligodendrocytes and activation of glial cells continue, with signs of demyelination and acute axonal pathology becoming evident (Crawford, 2009; Kipp, 2023).

Neuroinflammation time course for the cuprizone model

An overview of the neuroinflammation time course for the cuprizone model. During the cuprizone exposure period, there is a concurrent loss of myelin (purple) and a dramatic elevation in the populations of activated microglia & reactive astrocytes (pink) contributing to neuroinflammatory state. Both astrocytes and microglia play an active role in the removal of myelin debris, as well as the activation of the oligodendrocyte progenitors. Upon removal of the cuprizone insult and the remyelination of the axons, the neuroinflammation resolves.   

Between 3 and 5 weeks, demyelination becomes visible, and OPCs are activated and recruited to replace the lost oligodendrocytes (Brousse, 2015). Impaired motor coordination and behavioral deficits, primarily in spatial memory and social behavior, become evident (Franco-Pons, 2007). At this stage, if the cuprizone-containing diet is replaced with a standard diet, the demyelination process stops and remyelination occurs.

Demyelination and remyelination timeline for the cuprizone model

An overview of the demyelination and remyelination timeline for the cuprizone model. During the cuprizone exposure period, there is a concurrent loss of myelin (purple), death of mature oligodendrocytes (blue), and a dramatic elevation in proliferation and differentiation of oligodendrocyte progenitors (green) into pre-myelinating oligodendrocyte precursor cells (OPCs). The OPCs migrate and differentiate at the site of the tissue damage even while there is still cuprizone present. Upon removal of the cuprizone insult, the OPCs rapidly differentiate into mature oligodendrocytes, which begin remyelinating the exposed axons.

If the treatment is prolonged for over 12 weeks, the demyelination can become chronic, with the OPC population becoming exhausted and the potential for remyelination profoundly diminished (Lindner, 2009). Numerous studies have illustrated that the extended exposure to  cuprizone induces chronic lesions that show a limited endogenous remyelination capacity (Leo, 2022), prolonged astrogliosis (Hibbits, 2012), and more extensive axonal damage (Lindner, 2009). In summary, the cuprizone model is a crucial tool in MS research as it replicates key aspects of the disease, particularly oligodendrocyte degeneration and resulting demyelination. Understanding the timeline and mechanisms of cuprizone-induced damage is essential for developing targeted therapeutic interventions for MS.

What are the most common methods for assessing demyelination & remyelination in cuprizone mice?

To effectively study and understand the processes of demyelination and remyelination, it is crucial to employ reliable techniques for detecting myelin and the demyelination & remyelination processes within the central nervous system (CNS). Visualization of myelin in experimental tissues can be accomplished with histological & immunohistochemistry (IHC) techniques. Ultrastructural analysis of myelin sheaths can be visualized by electron microscopy (EM), providing high-resolution images. Advanced, non-invasive in vivo imaging techniques, such as magnetic resonance imaging (MRI), can provide insight into the ongoing process. While each of these techniques can facilitate a deeper understanding of myelin-related disorders, they each have pros and cons as outlined below.    

1. Histological Staining

There are a variety of histochemical techniques available for evaluation of demyelination and remyelination in cuprizone mice. A few commonly used staining methods are highlighted below.

Luxol Fast Blue (LFB)

Luxol Fast Blue (LFB) is a rapid histological stain used to provide insights into myelination in tissue sections. It effectively reveals clear voids where axonal tracts have been demyelinated, and is useful to identify the extent of myelin damage. The LFB method involves over-staining the tissue, followed by differentiation in lithium carbonate to distinguish between myelinated and demyelinated areas. The differentiation steps must be tailored to the specific tissues to achieve optimal staining. However, this process can generate significant batchwise variability, making LFB a poor candidate for quantitative analysis. 


FluoroMyelin™ and other Myelin-binding Fluorescent Stains

FluoroMyelin™ stains are commercially available fluorescent dyes that have selectivity affinity for myelin. These dyes have been developed in a number of different fluorescent colors that can be used to visualize myelin in combination with other markers within brain tissue sections. Numerous other fluorescent compounds that have an affinity for myelin have also been developed. The disadvantages of these fluorescent myelin binding compounds include a tendency to generate strong background staining, and showing low-staining contrast and often low brightness, thereby making them challenging to use in quantitative multiplex staining. 


Silver Staining

Silver staining is a very sensitive technique used for visualizing tissue structures, but it is a laborious procedure that requires tailored development times, leading to significant batchwise variability. Although it is highly sensitive, silver staining has a very low dynamic range and tends to stain various other proteinaceous structures, making it a poor candidate for quantitative analysis. 


Toluidine Blue

Toluidine Blue O is an anionic histological dye that binds to myelin (among other structures) and allows for detailed visualization of myelin wrapping. It is often used for peripheral nerves, and, while challenging, can be used within the CNS. The tissue preparation is laborious, as the process requires EPON resin embedding, and is most effective when staining semi-thin (0.5-1 μm) plastic-embedded tissue sections. Visualization of myelin within the corpus callosum requires detailed dissections, as the process is optimal in small tissue samples and sections must be perpendicular to the axons to visualize the myelin sheaths effectively. A disadvantage of this method is that it is time-consuming and does not allow for immunostaining of the same tissue. Additionally, Toluidine Blue O stains will bind to other structures, making careful tissue sampling crucial. 

2. Immunohistochemistry (IHC) Staining 

Immunohistochemical staining for myelin using markers, such as Myelin Basic Protein (MBP), Proteolipid Protein (PLP), and Myelin Oligodendrocyte Glycoprotein (MOG), on tissue sections is highly effective for identifying the myelin sheath associated with mature oligodendrocyte processes and cell bodies. This technique is excellent for quantifying myelin levels and visualizing the extent of myelin damage, but is not ideal for enumerating the number of myelin-producing cells. 

Immunohistochemical staining for oligodendrocyte lineage markers, such as Olig2/Olig2, PDGF-α-Receptor (PDGFRα), and NKX2.2, provide significant insights into the maturation and differentiation stages of oligodendrocyte precursor cells (OPCs). These markers are often localized in the nucleus or cell body, making them ideal for counting and tracking cell numbers during the OPC maturation and differentiation process. Olig2 is a transcription factor critical for involved in the proliferation and differentiation of oligodendrocytes. It is expressed in the nucleus of OPCs and continues to be expressed in mature oligodendrocytes. PDGFRα is a cell-surface receptor that binds platelet-derived growth factor (PDGF). It is a marker of early OPCs and is important for their proliferation and survival. PDGFRα expression is typically downregulated as OPCs differentiate into mature oligodendrocytes. NKX2.2 is a transcription factor that plays a crucial role in the differentiation of OPCs into mature oligodendrocytes. It is expressed in the nucleus and is involved in the regulation of genes necessary for oligodendrocyte maturation and myelination.

Immunohistochemical staining for Myelin Basic Protein (MBP) in multiple tissue sections, highlighting demyelination in the midline of the corpus callosum in a mouse exposed to cuprizone diet for a period of five weeks.

3. Electron Microscopy (EM) 

Electron microscopy offers ultra-high resolution images of tissue samples, providing exquisite details of myelin structure and wrapping at both the cellular and subcellular levels (Cruz-Martinez, 2016)It is utilized to determine the g-ratio of myelinated axons, and is an excellent technique for distinguishing developmentally myelinated axons from remyelinated axonsHowever, it samples only very small regions of the tissue, and in the cuprizone model, does not facilitate the insight into the extent of demyelination or remyelination throughout the corpus callosum.

lllustration of the g-ratio calculation

lllustration of the g-ratio calculation

4. In Vivo Imaging

Preclinical Magnetic Resonance Imaging (MRI) and Diffusion Tensor Imaging (DTI) allow for structural assessment due to the tissue-specific nature of water diffusion. Myelinated axons exhibit a characteristic constrained and directional DTI signal (Wang, 2019). These techniques can be performed as in-life assessments, providing insights into the evolution of myelin changes and are fully translatable (i.e. translational biomarkers) from preclinical efficacy studies to clinical trials (Sommer, 2022). 

Magnetization Transfer Ratio (MTR) (Tagge, 2016) is another MRI technique that provides insights into myelin content by measuring the transfer of magnetization between free water and macromolecule-bound water. This method, like DTI, can be performed as an in-life assessment, offering valuable information on the evolution of myelin changes. MTR is also translatable from preclinical efficacy studies to clinical trials (Sommer, 2022).

While powerful tools for non-invasive, longitudinal, in vivo assessment, MRI, DTI, and MTR do not allow for microscopic assessment and can be confounded by edema, although this issue is not a particular consideration for the cuprizone model given that vasogenic edema does not play a prominent role.

What are practical considerations for measuring demyelination & remyelination in preclinical therapeutic efficacy studies?

Important considerations when utilizing the cuprizone model for preclinical therapeutic efficacy studies as part of drug development studies include determining the appropriate time window for both the intervention and the endpoint readouts. The timing of intervention needs to take the pharmacokinetics (PK) of the therapeutic agent and the targeted cell type into consideration.  

Often a therapeutic effect will change the rate of the demyelination and remyelination phase, while ultimately the model will resolve to a very similar final remyelinated state. As such, selecting the most appropriate timing for endpoint assessments is also crucial. Given that demyelination and remyelination processes occur over different time frames, multiple time points should be evaluated to capture the dynamics of these processes.  

Choosing an appropriate pathological assessment is essential to generate objective and reproducible quantification. Ensuring that tissue preparation and sectioning allow for targeted localization of the pathology to the regions of the corpus callosum most impacted is important for cross-group comparisons.  

Maximizing insight into the evolution and resolution of the demyelinating & remyelinating lesion can be achieved by utilizing in vivo imaging. Techniques such as diffusion tensor imaging (DTI) and magnetization transfer imaging (MTR)  provide insights into white matter integrity. Longitudinal studies using MRI allow for repeated measures in the same animal, thereby enabling the tracking of disease progression and therapeutic effects.  

Our team would be happy to answer any questions about the Cuprizone Mouse Model or provide specific information about the MS models that we use for therapeutic efficacy studies.

Discover more about our MS Models


What is the typical number of cuprizone mice per group used in efficacy studies?

The sample size depends on the biological variability of the model and the methodological variability of the measures. In our studies using the cuprizone mouse model, we typically use 10-15 mice per group.

How do you choose the cuprizone concentration?

The optimum concentration of cuprizone to use should be established empirically in the testing facility with consideration for the experimental design and ideal treatment window for your investigation. It is also important to use the right strain, age (Irvine, 2006; Wang, 2013), and sex (Yu, 2017) of animals for optimal results.

What is the best method of administration of cuprizone?

Cuprizone at a concentration of between 0.2-0.3% in a powdered chow diet is the method of choice. Oral gavage has been suggested and while successful (Zhen, 2017), induces additional stress (and associated variability) into the experiment. Cuprizone formulation, including as pellets (Zheng, 2021), has been investigated by numerous groups (Hochstrasser, 2017), including the role of heat to potentially inactivate the reagent (Heckers, 2017). While the suggestion that heat may reduce activity levels has been debated, there is experimental evidence for the preparation of cuprizone influencing the demyelination window and anatomical location (Tommey, 2021).   

Are there obvious behavioral or clinical metrics for animals that have a demyelinated corpus callosum? 

While there are no overt clinical symptoms, such as loss of mobility or paralysis, as observed in other MS models (e.g. EAE), cuprizone-demyelinated mice exhibit more subtle motor and cognitive deficits. These deficits may be detectable in open-field and Y-maze cognition & memory assessments, as well as rotarod motor assessments (Franco-Pons, 2007).

Is axonal degeneration present in the cuprizone model?

While mild axonal damage may be present in the acute cuprizone model, more prominent injury is observed in the chronic model. The Experimental Autoimmune Encephalomyelitis (EAE) MS model also demonstrates injury to axons and should be considered if a putative therapeutic intervention targets axonal damage and degeneration.


Brousse, B., Magalon, K., Durbec, P., Cayre, M. Region and dynamic specificities of adult neural stem cells and oligodendrocyte precursors in myelin regeneration in the mouse brain. Biol. Open., 4: 980-992, 2015; doi: 10.1242/bio.012773.

Crawford, D.K., Mangiardi, M., Xia, X., López-Valdés, E., Tiwari-Woodruff, S.K. Functional recovery of callosal axons following demyelination: a critical window. Neurosci., 164: 1407–1421, 2009; doi: 10.1016/j.neuroscience.2009.09.069

Cruz-Martinez, P., González-Granero, S., Molina-Navarro, M., et al. Intraventricular injections of mesenchymal stem cells activate endogenous functional remyelination in a chronic demyelinating murine model. Cell Death Dis., 7: e2223, 2016; doi: 10.1038/cddis.2016.130. 

Dedoni, S., Scherma, M., Camoglio, C., Siddi, C., Dazzi, L., Puliga, R., Frau, J., Cocco, E., Fadda, P. An overall view of the most common experimental models for multiple sclerosis. Neurobiol. Dis., 184: 106230, 2023; doi: 10.1016/j.nbd.2023.106230. 

Franco-Pons, N., Torrente, M., Colomina, M.T., Vilella, E. Behavioral deficits in the cuprizone-induced murine model of demyelination/remyelination. Toxicol. Lett., 169: 205-213, 2007; doi: 10.1016/j.toxlet.2007.01.010

Gharagozloo, M., Mace, J.W., Calabresi, P.A. Animal models to investigate the effects of inflammation on remyelination in multiple sclerosis. Front. Mol. Neurosci., 15: 995477, 2022;  doi: 10.3389/fnmol.2022.995477.

Gudi, V., Gingele, S., Skripuletz, T., Stangel, M. Glial response during cuprizone-induced de- and remyelination in the CNS: lessons learned. Front. Cell. Neurosci., 8: 73, 2014; doi: 10.3389/fncel.2014.00073. 

Heckers, S., Held, N., Kronenberg, J., Skripuletz, T., Bleich, A., Gudi, V., Stangel, M. Investigation of cuprizone inactivation by temperature. Neurotox. Res., 31: 570-577, 2017; doi: 10.1007/s12640-017-9704-2

Hibbits, N., Yoshino, J., Le, T.Q., Armstrong, R.C. Astrogliosis during acute and chronic cuprizone demyelination and implications for remyelination. ASN Neuro., 4: 393-408, 2012; doi: 10.1042/AN20120062. 

Hiremath, M.M., Chen, V.S., Suzuki, K., Ting, J.P-Y., Matsushima, G.K. MHC class II exacerbates demyelination in vivo independently of T cells. J. Neuroimmunol., 203: 23–32, 2008; doi: 10.1016/j.jneuroim.2008.06.034.

Hochstrasser, T., Exner, G.L., Nyamoya, S., Schmitz, C., Kipp, M. Cuprizone-containing pellets are less potent to induce consistent demyelination in the corpus callosum of C57BL/6 mice. J. Mol. Neurosci., 61: 617-624, 2017; doi: 10.1007/s12031-017-0903-3

Irvine, K.A., Blakemore, W.F. Age increases axon loss associated with primary demyelination in cuprizone-induced demyelination in C57BL/6 mice. J. Neuroimmunol., 175: 69-76, 2006; doi: 10.1016/j.jneuroim.2006.03.002

Jhelum, P., Santos-Nogueira, E., Teo, W., Haumont, A., ILenoël, I., Stys, P.K., David, S. Ferroptosis mediates cuprizone-induced loss of oligodendrocytes and demyelination. J. Neurosci., 40: 9327-9341, 2020; doi: 10.1523/JNEUROSCI.1749-20.2020. 

Kipp, M. Astrocytes: lessons learned from the cuprizone model. Int. J. Mol. Sci., 24: 16420, 2023; doi: 10.3390/ijms242216420. 

Kipp, M. How to use the cuprizone model to study de- and remyelination. Int. J. Mol. Sci., 25: 1445-1461, 2024; doi: 10.3390/ijms25031445

Leo, H., Kipp, M. Remyelination in multiple sclerosis: findings in the cuprizone model. Int. J. Mol. Sci., 23: 16093, 2022; doi: 10.3390/ijms232416093. 

Lindner, M., Fokuhl, J., Linsmeier, F., Trebst, C., Stangel, M. Chronic toxic demyelination in the central nervous system leads to axonal damage despite remyelination. Neurosci. Lett., 453: 120-125, 2009; doi: 10.1016/j.neulet.2009.02.004. 

Rühling, S., Kramer, F., Schmutz, S., Amor, S., Jiangshan, Z., Schmitz, C., Kipp, M., Hochstrasser, T. Visualization of the breakdown of the axonal transport machinery: a comparative ultrastructural and immunohistochemical approach. Mol. Neurobiol., 56: 3984-3998, 2019; doi: 10.1007/s12035-018-1353-9. 

Sommer, R.C., Hata, J., Rimkus, C.M., Klein da Costa, B., Nakahara, J., Sato, D.K. Mechanisms of myelin repair, MRI techniques and therapeutic opportunities in multiple sclerosis. Mult. Scler. Relat. Disord., 58: 103407, 2022; doi: 10.1016/j.msard.2021.103407. 

Tagge, I., O'Connor, A., Chaudhary, P., Pollaro, J., Berlow, Y., Chalupsky, M., Bourdette, D., Woltjer, R., Johnson, M., Rooney, W. Spatio-temporal patterns of demyelination and remyelination in the cuprizone mouse model. PLoS One, 11: e0152480, 2016; doi: 10.1371/journal.pone.0152480. 

Toomey, L.M., Papini, M., Brittney, B., Wright, A.J., Warnock, A., McGonigle, T., Hellewell, S.C., Bartlett, C.A., Anyaegbu, C., Fitzgerald, M. Cuprizone feed formulation influences the extent of demyelinating disease pathology. Sci. Rep., 11: 22594, 2021; doi: 10.1038/s41598-021-01963-3

Vega-Riquer, J.M., Mendez-Victoriano, G., Morales-Luckie, R.A., Gonzalez-Perez, O. Five decades of cuprizone, an updated model to replicate demyelinating diseases. Curr. Neuropharmacol., 17: 129–141, 2019; doi: 10.2174/1570159x15666170717120343.

Walton, C., King, R., Rechtman, L., et al. Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition. Mult. Scler., 26: 1816-1821, 2020; doi: 10.1177/1352458520970841. 

Wang, H., Li, C., Wang, H., et al. Cuprizone-induced demyelination in mice: age-related vulnerability and exploratory behavior deficit. Neurosci. Bull., 29: 251–259, 2013; doi: 10.1007/s12264-013-1323-1

Wang, N., Zhuang, J., Wei, H., Dibb, R., Qi, Y., Liu, C. Probing demyelination and remyelination of the cuprizone mouse model using multimodality MRI. J. Magn. Reson. Imaging., 50(6): 1852-1865, 2019; doi: 10.1002/jmri.26758. 

Wolf, Y., Shemer, A., Levy-Efrati, L., Gross, M., Kim, J.S., Engel, A., David, E., Chappell-Maor, L., Grozovski, J., Rotkopf, R., Biton, I., Eilam-Altstadter, R., Jung, S. Microglial MHC class II is dispensable for experimental autoimmune encephalomyelitis and cuprizone-induced demyelination. Eur. J. Immunol., 48: 1308-1318, 2018; doi: 10.1002/eji.201847540. 

Yu, Q., Hui, R., Park, J., Huang, Y., Kusnecov, A.W., Dreyfus, C.F., Zhou, R. Strain differences in cuprizone induced demyelination. Cell. Biosci., 7: 59, 2017; doi: 10.1186/s13578-017-0181-3

Zhan, J., Mann, T., Joost, S., Behrangi, N., Frank, M., Kipp, M. The cuprizone model: dos and do nots. Cells, 9: 843, 2020; doi: 10.3390/cells9040843

Zhen, W., Liu, A., Lu, J., Zhang, W., Tattersall, D., Wang, J. An alternative cuprizone-induced demyelination and remyelination mouse model. ASN Neuro., 9: 1759091417725174, 2017; doi: 10.1177/1759091417725174

Zheng, F., Lin, Y., Boulas, P. Development and validation of a novel HILIC method for the quantification of low-levels of cuprizone in cuprizone-containing chow. Sci. Rep., 11: 17995, 2021; doi: 10.1038/s41598-021-97590-z.


Amyloid Precursor Protein (APP): a membrane protein that is highly expressed in neuronal synapses.

Axonal Injury: damage to the neuronal axon.

Cerebrospinal Fluid (CSF): an ultrafiltrate of plasma contained within the ventricles of the brain and the subarachnoid spaces of the brain and spinal cord.

Cuprizone: oxalic acid bis (cyclohexylidene hydrazide) [C14H22N4O2]; a copper chelating agent. 

Demyelination: a destructive process that causes damage to the myelin sheath that surrounds axons. In the central nervous system, the myelin sheath protects nerves in the brain, spinal cord and optic nerves. When this myelin sheath is damaged, the ability of the nerve to conduct electrical impulses slow or even stop.

Diffusion Tensor Imaging (DTI): an MRI technique that measures the diffusion and directionality of water, generating mean diffusivity, axial diffusivity, radial diffusivity, and fractional anisotropy metrics.

ELISA (Enzyme-Linked Immunosorbent Assay): a commonly used analytical biochemistry assay that detects the presence of a ligand (e.g. protein) in a liquid sample using antibodies directed against the ligand of interest. 

Experimental Autoimmune Encephalomyelitis (EAE): a commonly used autoimmune-mediated model of multiple sclerosis (MS) induced by CD4+ T cells specific for myelin-derived antigens, and characterized by paralysis resulting from inflammation, demyelination, axonal injury, and neurodegeneration in the central nervous system (CNS).

Ferroptosis: a type of programmed cell death distinct from apoptosis and necrosis, that involves the accumulation of iron and lipid peroxides in cells, ultimately leading to oxidative cell death.

Fluid Biomarker: a measure of disease obtain from bodily fluids, such as blood, cerebrospinal fluid (CSF), urine, sweat, tears, etc.

Immunohistochemistry (IHC): a laboratory technique to rapidly identify specific proteins in cells and tissues. IHC capitalizes on the ability of antibodies to target specific proteins, and then utilizes a sandwich of secondary antibodies and detection reagents to identify and localize the protein of interest in tissue sections at the microscopic level.

Magnetic Resonance Imaging (MRI): a non-invasive imaging modality that uses magnetic fields and radiofrequency (RF) pulses to generate images.

Microglia: one of the neuroglial cell types present in the brain and spinal cord. Constituting approximately 10-15% of the total cellular population in the brain, microglial cells function as the primary immune cells of the central nervous system. These cells are essential for maintaining homeostasis, clearing cellular debris, and providing critical support functions within the brain.

Multiple Sclerosis (MS): the most commonly demyelinating disease of the central nervous system (CNS); MS is an immune-mediated disease, involving T cell, B cells, microglia, and macrophages, and characterized by inflammation, demyelination, axonal injury, and neurodegeneration.

Myelin: a mixture of phospholipids and proteins that forms a concentric wrapped structure to ensheath an axon. Its primary function is to insulate the axon and enhance the speed and efficiency of electrical signal transmission.

Neurodegeneration: a complex, multifactorial process resulting in the loss of neurons. 

Neurofilament Light (NfL; NF-L): one of four subunits of neurofilaments, which are proteins found in neurons that provide structure and shape; the neurofilament light level in blood and CSF can serve as marker of neuro-axonal damage.

Oligodendrocyte: one of the neuroglial cell types present in the brain and spinal cord. Constituting approximately 20-40% of all glial cells, oligodendrocytes represent approximately 10-20% of all brain cells. Oligodendrocytes are the cells that  produce and maintenance the myelin sheath. A single oligodendrocyte will extend its processes to multiple axons, and ensheathing multiple segments with the protective myelin layers. 

Oligodendrocyte Precursor Cell (OPC): also known as Oligodendrocyte Progenitor Cell, a type of neural cell that has the potential to differentiate and mature into oligodendrocytes. OPCs are widely distributed throughout the CNS. They are present in both the gray and white matter of the brain and spinal cord, allowing them to respond to myelination needs in different regions. OPCs can respond to various signals in the CNS environment to either remain in a precursor state, proliferate, or differentiate into mature oligodendrocytes. This ability is crucial for both developmental myelination and remyelination following injury or disease.

Remyelination: the process by which new myelin sheaths are formed around axons in the central nervous system (CNS) following damage or loss of the original myelin. This process is crucial for restoring efficient neural function and protecting axons from further degeneration. Remyelination involves activation and migration of OPCs to the site of injury and differentiation of these activated OPCs into mature oligodendrocytes that will the extend processes to form new myelin sheaths.

Simoa (SIngle MOlecule Array): a sensitive digital immunoassay platform for measurement for fluid biomarkers.

Translational Biomarker: a robust indicator of a biological state or process that is measurable in both animal models and humans.

Related Content

Up-to-date information on Multiple Sclerosis and best practices related to the evaluation of therapeutic agents in MS animal models.

More Information

Let us know what you’re interested in. Our team will be happy to discuss with you!

Email us at i[email protected] or simply complete & submit the form below. 

Phone Number*
Affiliation (Company/University)*

Your privacy is important to us. We will protect your data as outlined in our Privacy Notice.

I agree to the terms in the Privacy Notice*

We use necessary cookies to make our site work. We also use other cookies to help us make improvements by measuring how you use the site or for marketing purposes. You have the choice to accept or reject them all. For more detailed information about the cookies we use, see our Privacy Notice.